Preferred Label : Anti-CD25 Antibody-drug Conjugate PF-08046032;
NCIt synonyms : ADC PF-08046032; Anti-CD25/MMAE ADC PF-08046032; Anti-CD25 ADC PF-08046032;
NCIt related terms : Anti-CD25 Antibody-drug Conjugate PF-08046032;
NCIt definition : An antibody-drug conjugate (ADC) composed of a detuned-affinity monoclonal antibody
directed against CD25 (interleukin-2 receptor subunit alpha; IL-2R alpha; IL-2Ra),
conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE),
with potential antineoplastic activity. Upon administration, anti-CD25 ADC PF-08046032
targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells.
Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and
inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest
and apoptosis in the Treg cells. This depletes Treg cells in the tumor microenvironment
(TME) and prevents immunosuppression, thereby enhancing anti-tumor immune responses.
CD25, the alpha chain of the IL-2 receptor, is highly expressed on Treg cells but
not on effector T (Teff) cells in tumors.;
Molecule name : PF-08046032; PF 08046032;
Origin ID : C216073;
concept_is_in_subset
- has_target
